Latest News

Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

New research explores the gut-brain connection, suggesting that improving gut health may enhance mental well-being.

A promising multistage malaria vaccine shows potential for broader protection against the disease, highlighting the evolving role of pharmacists in vaccination efforts.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

The FDA approved mitapivat, the first oral therapy for thalassemia anemia, offering hope for patients with transfusion-dependent and non–transfusion-dependent forms.

FDA approves mosunetuzumab's subcutaneous formulation, enhancing treatment access for relapsed follicular lymphoma.

Narsoplimab gains FDA approval for treating transplant-associated thrombotic microangiopathy, showing promising survival rates in high-risk patients.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

Medication errors are major public health issues, disproportionately affecting populations such as children, Ooder adults, and those with limited health literacy.

FDA approves lumateperone as a new adjunct therapy for major depressive disorder, offering hope for those with persistent symptoms despite treatment.

Six months following pneumococcal vaccination, over 70% of patients lost their protective titers, suggesting the need for more optimal vaccination strategies.

Nufymco, the FDA-approved ranibizumab biosimilar, enhances treatment options for retinal diseases, improving patient access and affordability.

Discover how AI-engineered nasal antiviral platforms revolutionize flu prevention, enhancing mucosal immunity and offering new treatment possibilities.

Sarah J. Billups, PharmD, highlights the disconnect between medication adherence metrics and actual patient outcomes, urging a reevaluation of adherence measures in health care.

Orforglipron shows promise in maintaining weight loss for individuals transitioning from injectable therapies, offering a convenient oral option for obesity management.

In patients with ST-segment elevation myocardial infarction, lowering low-density lipoprotein cholesterol to optimal levels prevented neoatherosclerosis, a complication following stent implantation.